Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Jazz Pharmaceuticals Therapeutics Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are distributed between 2 distinct examiners. Both of these pending matters are located within 1 distinct art unit, suggesting a close technical relationship between the applications.
The busiest examiner for the company is DAVIS, BRIAN J, who is handling 1 pending office action. This represents half of the 2 pending office actions currently active in the portfolio. The other action is assigned to the second of the 2 distinct examiners identified in the data.
The concentration of the workload within 1 distinct art unit in the Biotechnology & Pharmaceuticals sector indicates a focused prosecution strategy. DAVIS, BRIAN J is responsible for 1 pending office action, while the other is managed by a different examiner. This arrangement ensures that the company's 2 pending office actions receive individual attention from the 2 distinct examiners involved.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
| MAEWALL, SNIGDHA | 1 | 58.8% | +10.5% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18940070 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | DAVIS, BRIAN J | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17812414 | METHOD OF LYOPHILIZING LIPOSOMES | MAEWALL, SNIGDHA | 98d overdue |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18940070 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | DAVIS, BRIAN J | — | §101§112 | Non-Final OA | — | Pending | Nov 07, 2024 |
| 17812414 | METHOD OF LYOPHILIZING LIPOSOMES | MAEWALL, SNIGDHA | 1612 | DP | Non-Final OA | 98d overdue | Pending | Jul 13, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial